Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-2

Pralmorelin, Growth Hormone Releasing Peptide-2, KP-102

Quick Stats
Studies 230
Trials 1
Score 4
2008 pubmed

Secretagogues govern GH secretory-burst waveform and mass in healthy eugonadal and short-term hypogonadal men.

Veldhuis. Johannes D JD; Keenan. Daniel M DM

Key Findings

  • Combined infusion of GHRH and GHRP‑2 cuts the GH pulse duration from ~19 min to ~10 min.
  • The same secretagogues boost the amount of GH released per pulse by 40‑plus‑fold compared with saline.
  • Pulse frequency and variability stay the same, and the effect is unchanged in short‑term hypogonadal men.

Practical Outcomes

  • For biohackers, pairing GHRP‑2 with a GHRH analog (or using arginine to suppress somatostatin) can dramatically amplify GH spikes without increasing the number of pulses. This suggests a protocol that focuses on timing and combination rather than higher doses of a single peptide. Users should still monitor side effects and consider the short‑term nature of the effect, especially regarding hormone balance.

Summary

In healthy men, giving the peptide GHRP‑2 together with GHRH (or with arginine to block somatostatin) makes each growth‑hormone burst happen faster and releases a lot more GH – up to about 40‑times more than normal. The number of bursts doesn’t change, just their size and speed, and this works even when testosterone is briefly lowered.

Abstract

GH pulses are putatively initiated by hypothalamic GH-releasing hormone (GHRH), amplified by GH-releasing peptide (GHRP), and inhibited by somatostatin (SS). To ascertain how secretagogues control the waveform (time evolution of release rates) as well as the mass of secretory bursts. We quantified the shape of GH secretory bursts evoked by continuous combined i.v. infusion of maximally effective doses of GHRH and GHRP-2, and by bolus injection of each peptide after delivering L-arginine to restrain hypothalamic SS release in 12 healthy young men. A mathematically verified and experimentally validated variable-waveform deconvolution model was applied to intensively sampled GH time series. The secretory-burst mode (time from burst onset to maximal secretion) was 19+/-0.69 min during saline infusion, and fell to a) 10.4+/-3.0 min during constant dual stimulation with GHRH/GHRP-2 (P<0.01), b) 14.6+/-1.8 min after l-arginine/GHRH (P<0.025), and c) 15.0+/-1.0 min after l-arginine/GHRH (P<0.01). Secretagogues augmented the mass of GH secreted in pulses by 44-, 42-, and 16-fold respectively, over saline (2.2+/-0.81 microg/l per h; P<0.001 for each). Pulse number and variability were unaffected. Applying the same methodology to ten other young men with acute leuprolide-induced hypogonadism yielded comparable waveform and mass estimates. The present analyses in men demonstrate that peptidyl secretagogues modulate not only the magnitude but also the time course of the GH-release process in vivo independently of the short-term sex-steroid milieu.

Study Information

Provider

pubmed

Year

2008

Date

2008-08-14T00:00:00.000Z

DOI

10.1530/eje-08-0414